Galectin settles plans for phase 3 trial of NASH-cirrhosis therapy

Galectin Therapeutics announced plans for a phase 3 clinical trial of belapectin for patients with nonalcoholic steatohepatitis-related cirrhosis without esophageal varices, according to a press release.
“We are undertaking an adaptively designed trial that begins by confirming dose selection and the results observed in the NASH-CX trial,” Harold H. Shlevin, PhD, president and CEO of Galectin, said in the release. “An interim assessment of efficacy of belapectin, selection of an optimal dose and sizing will be conducted on an initial group of patients after 12 to 18 months of

Source link

Related posts

Insurance status linked with post-discharge outcomes in patients with cirrhosis


Stopping NASH in its tracks: Lifestyle Intervention Key from Day 1


ctDNA Levels May Help Predict Recurrence of Advanced Colon Cancer


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World